Objective To investigate the expressions of acid sensing ion channel 1a(ASIC1a) and activator protein-1 (AP-1) in hepatocellular carcinoma,and to analyze the relationship between expressions and clinical features.Methods At the transcription level,expression spectroscopy chips and bioinformatics were used to analyze the changes of signal pathways before and after ASICla interference in hepatocellular carcinoma cells.63 cases of HCC and 42 cases of tumor adjacent tissue samples were chosen from the Third People's Hospital of Wuxi,between January 2010 and December 2014.Immunohistochemical staining was utilized to detect the expressions of ASIC1 a,c-Jun,c-Fos.The relationships among the three were analyzed by the nonparametric Spearman rank correlation coefficient.Results After ASIC1a inhibition,the expression of AP-1 (c-Jun and c-Fox) decreased significantly.The expressions of c-Jun and c-Fox were greatly decreased in interference group compared with control group.The positive rates of ASIC1a,c-Jun and c-Fos in HCC tissues were significantly higher than that of the adjacent tissues,68.3％ vs.19.0％,55.6％ vs.11.9％,47.6％ vs.11.7％ (P ＜ 0.05).Correlation analysis showed that the expression of ASIC1a was positively correlated with c-Jun and c-Fos expression (r =0.404,0.309,P ＜ 0.05).The expressions of ASIC 1 a,c-Jun and c-Fos were not related to age,tumor diameter and gender (P ＞ 0.05),which were related to the clinical stage,AFP and lymph node metastasis of the tumor (P ＜ 0.05).Conclusion ASIC1a may.affect the development of hepatocellular carcinoma through the downstream gene AP-1.

Objective To observe the therapeutic effect of allogeneic hematopoietic stem cell transplantation(allo-HSCT)on acute myeloid leukemia(AML)and analyze the influencing factors of survival prognosis.Methods The clinical data of 32 AML patients who underwent allo-HSCT treat-ment were retrospectively analyzed.The hematopoietic reconstitution,occurrence of graft-versus-host disease(GVHD),survival status,recurrence,and transplantation-related mortality(TRM)of pa-tients were observed,and the influencing factors of survival prognosis were analyzed.Results All 32 AML patients who underwent allo-HSCT achieved granulocyte reconstitution,with a time range of 10 to 26 days and a median time of 11.0 days.Granulocyte-macrophage lineage reconstitution was achieved in 30 patients,with a time range of 10 to 54 days and a median time of 13.5 days.Among the 30 evaluable patients,10 developed acute GVHD(with incidence rate of 33.33％)and 10 developed chronic GVHD(incidence rate of 33.33％).Up to May 31,2023,the follow-up time ranged from 2 to 28 months,with a median follow-up time of 14.5 months.Of the 30 patients,28 survived(25 pa-tients were in disease-free survival status),and 2 died.Multivariate Cox regression analysis showed that age＞35 years(P=0.035,HR=2.021)and recurrence after transplantation(P=0.021,HR=2.546)were independent risk factors of patients'survival prognosis.Among 30 patients,5 relapsed,with a time range of 6 to 24 months and a median time of 9.0 months.Of 5 relapsed patients,2 died(non-TRM).Conclusion Allo-HSCT is an effective treatment for AML.Age＞35 years and recur-rence after transplantation are independent risk factors of patients'survival prognosis.

Objective To observe the therapeutic effect of allogeneic hematopoietic stem cell transplantation(allo-HSCT)on acute myeloid leukemia(AML)and analyze the influencing factors of survival prognosis.Methods The clinical data of 32 AML patients who underwent allo-HSCT treat-ment were retrospectively analyzed.The hematopoietic reconstitution,occurrence of graft-versus-host disease(GVHD),survival status,recurrence,and transplantation-related mortality(TRM)of pa-tients were observed,and the influencing factors of survival prognosis were analyzed.Results All 32 AML patients who underwent allo-HSCT achieved granulocyte reconstitution,with a time range of 10 to 26 days and a median time of 11.0 days.Granulocyte-macrophage lineage reconstitution was achieved in 30 patients,with a time range of 10 to 54 days and a median time of 13.5 days.Among the 30 evaluable patients,10 developed acute GVHD(with incidence rate of 33.33％)and 10 developed chronic GVHD(incidence rate of 33.33％).Up to May 31,2023,the follow-up time ranged from 2 to 28 months,with a median follow-up time of 14.5 months.Of the 30 patients,28 survived(25 pa-tients were in disease-free survival status),and 2 died.Multivariate Cox regression analysis showed that age＞35 years(P=0.035,HR=2.021)and recurrence after transplantation(P=0.021,HR=2.546)were independent risk factors of patients'survival prognosis.Among 30 patients,5 relapsed,with a time range of 6 to 24 months and a median time of 9.0 months.Of 5 relapsed patients,2 died(non-TRM).Conclusion Allo-HSCT is an effective treatment for AML.Age＞35 years and recur-rence after transplantation are independent risk factors of patients'survival prognosis.